MEDINET Co., Ltd. (JP:2370)
:2370
Want to see JP:2370 full AI Analyst Report?
2370 Stock Chart & Stats
¥29.00
-¥1.00(-2.70%)
At close: 4:00 PM EST
¥29.00
-¥1.00(-2.70%)
Day’s Range― - ―
52-Week Range¥24.00 - ¥43.00
Previous CloseN/A
Volume258.10K
Average Volume (3M)1.57M
Market Cap
¥7.00B
Enterprise Value¥4.88B
Total Cash (Recent Filing)¥5.03B
Total Debt (Recent Filing)¥91.32M
Price to Earnings (P/E)―
Beta0.42
Next Earnings
Aug 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.29
Shares Outstanding279,917,330
10 Day Avg. Volume1,137,840
30 Day Avg. Volume1,567,416
Financial Highlights & Ratios
PEG Ratio-3.12
Price to Book (P/B)2.45
Price to Sales (P/S)11.43
P/FCF Ratio-6.45
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageEffectively no debt materially reduces near-term solvency risk and gives management flexibility to raise capital or extend runway without immediate refinancing pressure. This durable capital-structure strength eases funding options while the company addresses operational losses.
Recent Revenue GrowthRecovering top-line (+11.8% in FY2025) indicates service demand and traction in core clinical research offerings. Sustained revenue growth, if maintained, creates a base to leverage fixed costs, stabilize margins, and improve cash generation over the medium term.
Structural Industry DemandThe company serves medical and clinical research—a sector with secular tailwinds from drug development and regulatory complexity. Persistent industry demand for specialized support services provides a durable addressable market for revenue stability and long-term contract opportunities.
Bears Say
Persistent Large LossesVery large and persistent net losses materially weaken internal ability to fund operations or invest in growth. Over months this erodes strategic optionality, forces reliance on external financing, and increases execution risk if profitability improvement is not achieved.
Worsening Cash Flow / Cash BurnSharp deterioration in free cash flow shows losses convert to real cash burn, reducing runway and increasing the probability of dilution or debt raising. This structural cash shortfall constrains capital for R&D, sales expansion, or margin-improvement initiatives over the next several months.
Margin Deterioration And Equity ErosionFalling equity and sharply lower gross margins (gross margin ~13.5% in FY2025 vs ~37.2% in FY2020) reduce the company's loss-absorption capacity. This structural margin erosion raises break-even requirements and accelerates equity depletion absent durable margin recovery.
MEDINET Co., Ltd. News
2370 FAQ
What was MEDINET Co., Ltd.’s price range in the past 12 months?
MEDINET Co., Ltd. lowest stock price was ¥24.00 and its highest was ¥43.00 in the past 12 months.
What is MEDINET Co., Ltd.’s market cap?
MEDINET Co., Ltd.’s market cap is ¥7.00B.
When is MEDINET Co., Ltd.’s upcoming earnings report date?
MEDINET Co., Ltd.’s upcoming earnings report date is Aug 07, 2026 which is in 55 days.
How were MEDINET Co., Ltd.’s earnings last quarter?
MEDINET Co., Ltd. released its earnings results on May 13, 2026. The company reported -¥0.78 earnings per share for the quarter, missing the consensus estimate of N/A by -¥0.78.
Is MEDINET Co., Ltd. overvalued?
According to Wall Street analysts MEDINET Co., Ltd.’s price is currently Overvalued.
Does MEDINET Co., Ltd. pay dividends?
MEDINET Co., Ltd. does not currently pay dividends.
What is MEDINET Co., Ltd.’s EPS estimate?
MEDINET Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does MEDINET Co., Ltd. have?
MEDINET Co., Ltd. has 279,917,330 shares outstanding.
What happened to MEDINET Co., Ltd.’s price movement after its last earnings report?
MEDINET Co., Ltd. reported an EPS of -¥0.78 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of MEDINET Co., Ltd.?
Currently, no hedge funds are holding shares in JP:2370
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
MEDINET Co., Ltd.
Established in 1995 and headquartered in Tokyo, Japan, MEDINET Co., Ltd. functions as a contract development and manufacturing organization (CDMO) primarily focused on regenerative medicine and cell therapy solutions within Japan. The company furnishes comprehensive support for immuno-cell therapy, encompassing critical elements such as specialized technical expertise, advanced facilities, robust operational systems, essential materials, and skilled cell engineers. Furthermore, MEDINET actively manufactures regenerative medical products, investigational cell products, and other specified cell-based therapies. Its extensive value chain offerings also cover personnel training, facility and equipment design, operational management, standard operating procedure (SOP) preparation, logistics networks, information systems, purchasing and production management, stringent quality management and assurance, and technology transfer and process development. The firm actively collaborates with and supports medical institutions, research organizations, and biopharmaceutical companies in their endeavors to advance immuno-cell therapy.
Technical Analysis
Linical Co., Ltd.
―
Trans Genic Inc.
―
Soiken Holdings Inc.
―
Takara Bio Inc.
―
PRISM BioLab Co. LTD
―